Top-line results showing that type 1 diabetics treated with the dual SGLT inhibitor sotagliflozin achieved statistically significant reductions in A1C at 24 weeks in a pivotal phase III trial drew fresh enthusiasm for Lexicon Pharmaceuticals Inc. Friday, pushing shares 16.6 percent higher and encouraging partner Sanofi SA.